Stock comparison
LeMaitre Vascular
Tarsus Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TARS
Tarsus Pharmaceuticals
Market cap
$2.68B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TARS | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 22F | LMAT |
| Benjamin Graham | 89A | 57D | LMAT |
| Philip Fisher | 81C | 50C | LMAT |
| Peter Lynch | 67B | 47D | LMAT |
| Joel Greenblatt | 56D | 2F | LMAT |
| Charlie Munger | 68D | 31F | LMAT |
| Terry Smith | 69D | 30F | LMAT |
Side-by-side metrics
| Metric | LMAT | TARS |
|---|---|---|
| Market cap | $2.23B | $2.68B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -11.54% |
| Gross margin | 72.39% | 90.44% |
| Net margin | 24.35% | -9.02% |
| Revenue CAGR 5y | 12.75% | 67.73% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.3x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- ROIC (TTM)9.43%vs -11.54%+182%
- Net margin24.35%vs -9.02%+137%
- Dividend yield0.84%vs 0.0%+100%
TARS leads on
- EV/EBIT-vs 36.6x+197%
- P/E (TTM)-vs 37.1x+171%
- Revenue CAGR 5y67.73%vs 12.75%+81%
- Debt / Equity0.3xvs 0.5x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.